References
- Dreis S, Rothweiler F, Michaelis M, Cinatl J, Jr, Kreuter J, Langer K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm 2007; 341: 207–214
- Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2: 347–60
- Eatock M, Church N, Harris R, Angerson W, McArdle C, French R, Twelves C. Activity of doxorubicin covalently bound to a novel human serum albumin microcapsule. Invest New Drugs 1999; 17: 111–120
- Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev 2003; 22: 165–190
- Eyer P, Worek F. Oximes. Chemical warfare agents, 2nd, TC Marrs, RL Maynard, FR Sidell. Wiley, New York 2007; 305–329
- Gunnell D, Eddleston M. Suicide by intentional ingestion of pesticides: A continuing tragedy in developing countries. Int J Epidemiol 2003; 32: 902–909
- Guo C, Gemeinhart RA. Understanding the adsorption mechanism of chitosan onto poly(lactide-co-glycolide) particles. Eur J Pharm Biopharm 2008; 70: 597–604
- Hekmatara T, Bernreuther C, Khalansky AS, Theisen A, Weissenberger J, Matschke J, Gelperina S, Kreuter J, Glatzel M. Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects. Clin Neuropathol 2009; 28: 153–164
- Jung T, Kamm W, Breitenbach A, Klebe G, Kissel T. Loading of tetanus toxoid to biodegradable nanoparticles from branched poly(sulfobutyl-polyvinyl alcohol)-g-(lactide-co-glycolide) nanoparticles by protein adsorption: A mechanistic study. Pharm Res 2002; 19: 1105–1113
- Kreuter J. Nanoparticles—a historical perspective. Int J Pharm 2007; 331: 1–10
- Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Contr Rel 2007; 118: 54–58
- Langer K, Anhorn MG, Steinhauser I, Dreis S, Celebi D, Schrickel N, Faust S, Vogel V. Human serum albumin (HSA) nanoparticles: Reproducibility of preparation process and kinetics of enzymatic degradation. Int J Pharm 2008; 347: 109–117
- Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 2003; 257: 169–180
- Langmuir I. The constitution and fundamental properties of solids and liquids. Part I: Solids. J Am Chem Soc 1916; 38: 2221–2295
- Leo E, Brina B, Forni F, Vandelli MA. In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. Int J Pharm 2004; 278: 133–141
- Li XG, Feng H, Huang MR. Strong adsorbability of mercury ions on aniline/sulfoanisidine copolymer nanosorbents. Chemistry 2009; 15: 4573–4581
- Lundy PM, Shih TM. Examination of the role of central cholinergic mechanisms in the therapeutic effects of HI-6 in organophosphate poisoning. J Neurochem 1983; 40: 1321–1328
- Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K. Covalent linkage of apolipoprotein E to albumin-nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 2006; 317: 1246–1253
- Paudyal BP. Organophosphorous poisoning. J Nepal Med Assoc 2008; 47: 251–258
- Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002; 23: 3247–3255
- Richardson NE, Meakin BJ. The sorption of benzocaine from aqueous solution by nylon 6 powder. J Pharm Pharmacol 1974; 26: 166–174
- Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Contr Rel 2001; 70: 1–20
- Spöhrer U, Eyer P. Separation of geometrical syn and anti isomers of obidoxime by ion-pair high-performance liquid chromatography. J Chromatogr A 1995; 693: 55–61
- Steinhauser I, Spankuch B, Strebhardt K, Langer K. Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells. Biomaterials 2006; 27: 4975–4983
- Ueda M, Iwara A, Kreuter J. Influence of the preparation methods on the drug release behaviour of loperamide-loaded nanoparticles. J Microencapsul 1998; 15: 361–372
- Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009; 71: 251–256
- Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 2004; 12: 461–471
- Washington C. Evaluation of non-sink dialysis methods for the measurement of drug release from colloids: Effects of drug partition. Int J Pharm 1989; 56: 71–74
- Washington C. Drug release from microdisperse systems: A critical review. Int J Pharm 1990; 58: 1–12
- Weber C, Kreuter J, Langer K. Desolvation process and surface characteristics of HSA-nanoparticles. Int J Pharm 2000; 196: 197–200
- Worek F, Widmann R, Knopff O, Szinicz L. Reactivating potency of obidoxime, pralidoxime, HI 6 and HLo 7 in human erythrocyte acetylcholinesterase inhibited by highly toxic organophosphorus compounds. Arch Toxicol 1998; 72: 237–243
- Yoo HS, Oh JE, Lee KH, Park TG. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm Res 1999; 16: 1114–1118
- Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Buchel C, von Briesen H, Kreuter J. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Contr Rel 2009; 137: 78–86